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Impaired plasma triglyceride clearance as a feature of both ure-
mic and posttransplant triglyceridemia. After accurate plasma
volume calculation, endogenous plasma very-low-density-lipo-
protein (VLDL) -triglyceride turnover rates were measured in 20
undialyzed patients with chronic renal failure (CRF) and in 16
renal transplant recipients with stable graft function. When ki-
netic criteria were based on a group of healthy subjects (Vmax
36.7 moles/hr/kg), it was clear that, on the whole, CRF patients
had a reduced capacity for VLDL-triglyceride removal (Vmax
14.0 jmoles/hr/kg), as did graft recipients (Vmax 19.5 moles/
hr/kg). In transplant recipients with impaired graft function,
however, extremes of both under removal and over production
of VLDL-triglycerides were observed. In CRF, defective clear-
ance was accompanied by a reduction in postheparin lipoprotein
and hepatic lipase activities, although there was no statistical
relationship. Enzyme activities were not reduced, however, after
transplantation, and the metabolic factors responsible for defec-
tive clearance were not clearly identified.
Diminution de Ia clearance plasmatique des triglycerides, un as-
pect de Ia triglyceridemie urémique et de post-transplantation.
Après un calcul précis du volume plasmatique, Ic renouvellement
des lipoprotéines de faible densité, triglycérides-(VLDL), du
plasma a été mesuré chez vingt tnalades non dialyses atteints
d'insuthsance rénale chronique (CRF) et seize receveurs de
transplants rCnaux avec une fonction stable. Quand les critéres
cinétiques sont évalués a partir d'un groupe de sujets normaux
(Vmax = 36,7 smoles/heure/kg), it est clair que, dans l'en-
semble, les malades atteints de CRF ont une capacité réduite
d'extraction de VLDL-triglycérides (Vmax = 14 moles/heure/
kg) de méme que les receveurs de greffes (Vmax = 19,5 smoles/
heure/kg). Cependant, chez les receveurs de grefes a fonction
altérée des valeurs extremes d'extraction abaissée et de produc-
tion augmentée ont etC observées. Chez les patients atteints de
CRF, l'abaissement de la clearance est accompagné d'une ré-
duction des activités lipoprotéine et lipase hépatique post-hCpa-
rime bien qu'iI n'y ait pas de relation statistique. Cependant les
activités enzymatiques n'étaient pas diminuées après trans-
plantation et les facteurs métaboliques responsables du deficit de
clearance n'ont pas Cté clairement identifies.
The determination of whether overproduction or
underutilization is responsible is an essential step
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for the elucidation of the pathogenesis of the hyper-
lipoproteinemias. Although elevated circulating lip-
id concentrations are found both in chronic renal
failure (CRF) and after renal transplantation, the
lipoprotein profile is different. Very-low-density-lip-
oprotein (VLDL) is raised, and high-density-lipo-
protein (HDL) lowered, in CRF, whereas kidney
transplant recipients show a variable pattern, with
either VLDL or low-density-lipoprotein (LDL), or
both, increased [1]. This observation indicates that
the underlying metabolic abnormality is not the
same in the two conditions.
In CRF, diminished peripheral utilization of tri-
glyceride appears to be responsible for elevated
plasma VLDL levels. Reduced activity of plasma
lipases, which are believed to mediate the transfer
of neutral fat from plasma to liver, adipose tissue,
and muscle, is a frequent finding in uremic patients
[2-4], and diminished clearance rates for infused
synthetic triglyceride have been demonstrated both
in uremia and after transplantation [2]. These two
methods for assessing triglyceride utilization have
limitations, however; and a preferable approach is
simultaneous estimation of VLDL production and
removal by the measurement of endogenous
VLDL-triglyceride (VLDL-TG) turnover in the
steady state [5, 6]. This has been done in both Un-
dialyzed [7, 8] and dialysis-treated [9, 10] patients
with CRF, and in all four studies, defective clear-
ance was implicated as the principal cause of ure-
mic hypertriglyceridemia. In each, calculation of
the individual turnover rates depended on an esti-
mate of plasma volume based on body weight.
Plasma volume, however, is usually expanded in
renal failure [4, 11], and this in itself would partially
account for reduced turnover rates reported by
these authors. We have repeated these studies of
endogenous VLDL-TG turnover in undialyzed
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CRF, but with simultaneous measurement of
plasma volume and determination of postheparin
lipoprotein and hepatic lipase activities.
A single study of endogenous VLDL-TG turn-
over in kidney transplant recipients has been pub-
lished recently [12]. The authors concluded that
VLDL-TG overproduction was principally respon-
sible for transplant hypertriglyceridemia. To con-
firm or deny this finding, we have extended our ob-
servations to a representative group of patients with
functioning renal allografts.
Methods
Subjects (Table 1). The patients studied were all
attending the renal clinic at Sydney Hospital. None
was diabetic, nephrotic (past or present), or suf-
fered from any other disorder associated with
plasma lipid abnormalities. Twenty patients (9
males and 11 females) with advanced CRF resulting
from a variety of causes [13] were not being, and
had never been, treated by dialysis. These 20 were
taking diets restricted in protein (to 0.5 g or less per
kilogram of body weight) but not in any other way.
A further 16 patients (10 males and 6 females) had
received cadaveric kidney transplants 2 months to
10 years prior to this study (Table 2). All of the graft
recipients had stable renal function without evi-
dence of acute rejection, and none had been treated
with bolus i.v. glucocorticoid for at least 1 month
prior to study. They were receiving immuno-
suppressive therapy consisting of daily oral predni-
sone (7.5 to 25.0 mg/day) and azathioprine (0 to 200
mg/day). Ten of the CRF patients and three of the
transplant recipients were receiving medication for
hypertension. These patients did not differ from
those not receiving antihypertensive therapy in any
of the parameters studied, and therefore have been
included in the analyses.
The two groups of patients were compared with a
series of 10(4 males and 6 females) healthy controls
of similar age and relative body weight (actual
weight as a percentage of mean ideal weight for
height and sex) [14] on ad lib diets and taking no
drugs.
Protocol of clinical investigation. All subjects
were fasted for at least 10 hours overnight prior to
the study. At 8 A.M. baseline venous blood was
drawn into plain glass tubes (for serum insulin),
Vacutainer (Becton-Dickinson, Rutherford, New
Jersey) tubes containing EDTA (for lipids), and
tubes containing fluoride oxalate (for blood sugar,
in transplant recipients only).
Two hundred microcuries of glycerol-2-3H (Searle
Laboratories) were then injected i.v. for the deter-
mination of VLDL-TG turnover according to the
method of Farquhar et al [5]. Further blood samples
were taken into EDTA-containing tubes at 2, 2'/2, 3,
4, 5, 6, and 8 hours after injection. Subjects con-
tinued to fast throughout the test, but water was
allowed and all were encouraged to walk about the
ward.
At the conclusion of the isotope study, heparin
(Boots, Nottingham), 50 U/kg, was injected i.v. Af-
ter 15 mm, blood was drawn directly into trisodium
citrate (1.2 mmole s/liter final concentration) -con-
taining tubes cooled to 4° C. The postheparin
plasma so obtained was kept frozen at —20° C until
immediately before assay for lipases.
Plasma volume was then determined in renal fail-
ure and transplant patients by the Evan's Blue
(T1824) dye-dilution technique [15]. The plasma
volume of control subjects was estimated at 45 ml/
kg of body wt [16] after pilot studies by the Evan's
Blue method had revealed actual volumes very
close to this estimate in 6 normal male (mean, 44.5
[SD] 3.7 mI/kg) and 7 normal female (mean, 44.6
[SD] 9.7 mllkg) subjects.
Table 1. Basic clinical and laboratory dataa
No. and
sex
Age
yr
Relative wt
%
Serum concentrations
Cholesterol
mrnoles/liter
Triglycerides
mmoles/liter
Creatinine
mmoles/liter
Insulin
U/liter
Healthy controls
Chronic renal failure
Renal transplantation
(4M, 6F)
(9M, llF)
(tOM, 6F)
42 16
(23to64)
42 14
(18to59)
42 11
(25to53)
98 10
(82toll9)
95 14
(73to131)
97 14
(71 to 125)
5.7 0.9
(4.2to7.0)
4.9 1.1
(3.lto6.8)
5.5 1.1
(3.7to7.4)
0.99 0.49
(0.43to2.14)
2.33 0.81
(1.05to3.83)c
1.79 0.77
(0.66to3.45)'
—
1.36 0.55
(0.52to2.97)
0.13 0.05
(0.O7toO.24)
—
(0.43to2.14)
20.3 9.8
(10.0to45.5)
17.7 5.6
(8.8to29.9)
Results are expressed as the means SD (ranges are given in parentheses).
°P <0.01, compared with controls.
<0.001, compared with controls.
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Table 2. Detailed data for renal transplant group
Subject
no. Sex
Time since
graft
months
Relative body
wt
%
Average prednisone in
month prior to study
mg/day
Serum
creatinine
mmoles/liter
Serum
triglycerides
mmoles/liter
Fasting serum
insulin
U/liter
Fasting
blood glucose
mmoles/liter
1 M 3 95 26 0.11 2.34 12.0 —
2 M 15 111 10 0.11 2.99 17.5 4.3
3 M 28 88 10 0.14 0.85 13.0 —
4 M 12 107 20 0.14 1.36 15.3 5.0
5 M 112 125 10 0.13 2.16 20.0 4.1
6 M 40 106 9 0.09 1.95 12.0 4.7
7 M 29 96 25 0.13 1.73 29.9 5.0
8 M 118 98 10 0.09 1.10 20.0 4.1
9 M 13 98 30 0.20 1.60 19.6 4.3
10 M 6 97 16 0.24 2.64 16.5 4.2
11 F 2 75 35 0.08 1.73 16.0 3.4
12 F 114 89 8 0.07 0.66 8.8 3.9
13 F 47 119 10 0.08 1.25 20.0 3.3
14 F 4 88 18 0.09 1.18 18.0 4.8
15 F 6 95 25 0.17 1.59 16.2 5.0
16 F 48 71 25 0.24 3.45 28.5 3.6
Means SD 37 41 97 14 18 9 0.13 0.05 1.79 0.77 17.7 5.6 4.3 0.6
Biochemistry. Total cholesterol and triglyceride
and VLDL-TG were determined in isopropanol ex-
tracts of the 8 A.M. plasma samples by the Autoana-
lyzer (Technicon methods N-24a and N-78, respec-
tively). Serum insulin was determined by radioim-
munoassay [17]. Blood glucose was measured by
the glucose oxidase method [18].
VLDL-TG turnover. VLDL were separated from
each of the plasma samples by ultracentrifugation at
X 105,000g for 16 hours [19]. The VLDL fractions
were then extracted into isopropanol and analyzed
for triglyceride mass and radioactivity after treat-
ment with Zeolite to remove phospholipid.
For the 46 studies, the average coefficient of vari-
ation of VLDL-TG concentration during the 8 hours
of study was 10.8%, and there was no significant
effect of time on the levels. It was thus assumed that
steady-state conditions pertained. During each indi-
vidual study, the specific activity of VLDL-TG de-
cayed exponentially. In all instances documented
here, this decay occurred after 2 hours and ap-
peared monoexponential, as is illustrated in Fig. 1.
For analytical purposes, it was therefore assumed
that all VLDL-TG-3H input into the plasma space
had occurred by 2 hours and that decay between 2
and 8 hours was monoexponential; when such stud-
ies are continued up to 24-48 hours, a second ex-
ponent may become apparent [20]. We studied
three patients with CRF in whom the decay could
not be resolved by a single exponent; data from
these patients have not been included in this paper.
Fractional and absolute turnover rates were cal-
culated mathematically from the regression line that
was drawn from the semilogarithmic plot of specific
activity vs. time using the method of least squares:
(1) fractional turnover rate (k) = 0.6931t'12 (t'/2
= half time of disappearance of labeled plasma
VLDL-TG).
(2) VLDL-TG plasma pool size = VLDL-TG
concentrations (S) X plasma volume.
k X pool size(3) absolute turnover rate (V) = ____________
body weight
In the steady state, turnover rate equals removal
rate of VLDL-TG, which equals its production rate.
This equivalence allows inferences to be made con-
cerning the relationship between VLDL-TG pro-
duction rate and concentration.
On the basis of previous observations [5—10], it
was assumed that the removal mechanisms for
VLDL-TG would conform to the kinetics of a satu-
rable system. In these circumstances, the relation-
ship between V and S is given by a rectangular hy-
perbola, according to the Michaelis-Menten equa-
tion:
_VmaxxS— (S + Km)
where Vmax = the maximum turnover rate of the
system and Km= the value of S at which V = 'Iz
Vmax.
A plot of individual S/V (ordinate) against S (ab-
scissa) values allows linear conversion of the data
so that a fitted regression line will have a slope of 1/
Vmax and an intercept on the abscissa equal to KmI
Vmax. This allows calculation of Km and Vmax for
each group of subjects.
Plasma lipases. The details of the quantification
of postheparin lipases are documented elsewhere
[4]. Briefly, lipoprotein lipase and hepatic tn-
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Fig. 1. Representative specific activity-time curves for VLDL-TG after the injection of 200 ,.Ci of glvcerol-2-3H at time 0 in a a healthy
control, b a patient with chronic rena/failure, and c a renal transplant recipient.
glyceride lipase were separated from the whole
postheparin plasma by affinity chromatography us-
ing cyanogen-bromide-activated agarose to which
heparin had been covalently bound [21]. The sepa-
rate enzyme fractions were incubated with a soni-
cated lecithin-stabilized triolein emulsion labeled
with 14C-triolein, and the 14C-oleate thus released
was extracted and counted in a liquid scintillation
spectrometer. An aliquot of pooled plasma from
healthy subjects was included in the incubation me-
dium as a source of apoprotein C-Il cofactor for the
assay of lipoprotein lipase. Enzyme activity was ex-
pressed as micro moles of nonesterified fatty acid re-
leased per hour per milliliter of plasma.
Statistical calculations. Results were analyzed
by conventional parametric methods including Stu-
dent's t test and linear regression analysis using a
programmable desk calculator. Group data are giv-
en as the mean 1 SD.
Results
The CRF and transplant recipient groups were
similar to the healthy control group in age, relative
body weight, and serum cholesterol levels, and
their basal serum insulin levels fell within, or close
to, the normal range (Table 1). Serum triglycerides,
however, were significantly elevated, more so in
CRF (P < 0.001) than after transplantation (P <
0.01).
There was a significant positive correlation be-
tween serum total triglyceride levels and creatinine
concentrations in the transplantees (r = 0.56, P <
0.05); and in four individual transplantees who had
impaired graft function (serum creatinine con-
centratons > 0. 15 mmoles/liter), the triglyceride
levels tended to be higher (mean, 2.33 0.95
mmoles/liter) than in the transplant group as a
whole. Total triglyceride levels in the transplant
group, however, failed to show a significant correla-
tion with any other parameter listed in Table 2, in-
cluding time since grafting, daily dose of predni-
sone, relative body weight, basal serum insulin, or
fasting blood sugar. There was no correlation be-
tween creatinine and total triglyceride levels in
CRF.
VLDL-TG turnover (Table 3). Plasma volumes
were, on average, 20% higher in CRF patients than
in controls, but were normal in transplant recipi-
ents.
VLDL-TG concentrations were higher, the pool
sizes expanded, and the fractional turnover reduced
in CRF, whereas in each case values for transplant
recipients lay between the CRF and the normal
groups (Table 3). In the transplant group, VLDL-
TG concentrations showed a significant positive
correlation (r = 0.53, P < 0.05) with serum creati-
nine concentrations but no significant correlation
with other parameters in Table 2. Total turnover, in
absolute values, did not vary significantly between
the three groups and could not be correlated with
serum creatinine, basal insulin concentration, or
relative body weight in any group, nor with time
since grafting, prednisone dose, or fasting blood
sugar in the transplant group.
Linear conversion of the kinetic data for the con-
trol group was satisfactory (r = 0.81), yielding a rec-
tangular hyperbola with a Km of 1375 moles/liter
and a Vmax of 36.7 moles/hr/kg of body wt. When
V (turnover) versus S (VLDL-TG concentration)
coordinates of the CRF patients were plotted (Fig.
2a), 16 out of the 20 lay below and to the right of the
control hyperbola, indicating a defect in VLDL-TG
clearance. Two patients with elevated VLDL-TG
concentrations (> 900 /Lmoles/liter) had coordinates
close above the hyperbola, denoting over-produc-
tion. Two patients had coordinates within the nor-
mal group. Linear conversion of all CRF coordi-
nates was also satisfactory (r = 0.74), but the ex-
1000
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0
>
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Table 3. Turnover data
VLDL-TG
Plasma Plasma VLDL-TG VLDL-TG Fractional turnover
volume (S) pool size turnover rate rate (V)
Sex mi/kg j.wioies/hter pinoles hr1 p.moles/hr/kg
Healthy controls
M 45 400 1,432 0.53 9.5
M 45 500 1,350 0.39 8.7
M 45 480 1,435 0.40 7.9
M 45 350 1,427 0.69 10.9
F 45 420 1,230 0.39 7.4
F 45 600 1,544 0.41 11.2
F 45 150 425 0.46 3.1
F 45 270 675 0.50 6.2
F 45 1,568 5,151 0.28 19.8
F 45 280 589 0.58 7.4
Means SD 45 500 397 1,525 1,338 0.46 0.12 9.2 4.4
M 62 1,380
Chronic renalfailure
3,580 0.22 18.8
M 53 2,160 9,702 0.12 13.8
M 52 1,910 7,502 0.08 8.0
M 61 1,180 4,532 0.08 5.8
M 69 700 2,983 0.17 8.3
M 50 1,480 5,544 0.14 10.4
M 64 850 4,397 0.14 7.6
M 63 1,900 7,934 0.08 9.6
M 48 1,050 3,900 0.14 7.0
F 45 1,360 3,461 0.32 19.8
F 56 1,630 3,291 0.12 10.9
F 56 880 2,666 0.25 12.2
F 59 150 492 0.40 3.5
F 64 1,360 5,081 0.12 10.5
F 46 2,600 5,600 0.11 13.1
F 34 2,130 4,214 0.20 14.4
F 53 720 3,238 0.27 10.1
F 48 2,730 6,922 0.07 9.2
F 54 860 2,092 0.14 6.5
F 53 730 5,626 0.15 14.8
Means SD 54 8 1,390 680d 4,638 2,180d 0.17 0.09' 10.7 4.2
M 46 1,310
Renal transplantation
4,081 0.21 12.6
M 32 1,090 3,147 0.25 8.7
M 50 660 2,116 0.36 11.9
M 42 900 2,836 0.51 19.0
M 45 1,640 6,126 0.21 15.3
M 39 910 2,452 0.25 8.8
M 49 1,100 3,428 0.17 9.1
M 39 480 1,316 0.58 10.9
M 47 880 2,669 0.23 9.4
M 49 1,200 4,052 0.18 10.6
F 41 770 1,475 0.32 10.2
F 35 180 326 0.53 3.4
F 45 1,110 3,608 0.28 13.9
F 41 730 1,826 0.25 7.5
F 56 1,280 3,764 0.39 28.2
F 57 1,590 3,822 0.05 4.5
Means SD 45 7 989 382C 2,940 1,384tC 0.30 0.14e 11.5 59
See text.
P <0.05, compared with controls.
P < 0.01, compared with controls.
p < 0.001, compared with controls.
trapolated Km (455 moles/liter) and Vmax (14.0
moles/hr/kg) were much lower than were those for
the control group.
Examination of the V/S coordinates of the trans-
plant recipients (Fig. 2b) showed that three were
within the normal group; of the remainder, 11 were
clearly below and to the right of the control hyper-
bola, indicating under-removal, though less so than
for the CRF coordinates. Two patients with ele-
vated VLDL-TG levels had coordinates well above
the hyperbola, indicating over-production. These
overproducers could not readily be distinguished
0,
0
0C
S
b
-J
-J
>
from the other transpiantees by virtue of the param-
eters listed in Table 2. The two pairs of coordinates
denoting extremes of overproduction and underre-
moval in the transplant population were those of re-
cipients with impaired renal function (serum creati-
nine levels, 0.17 and 0.24 mmoles/liter, respective-
ly). The heterogeneity of the transplant group was
evidenced by poor linear conversion (r = 0.57) of all
coordinates; when those with serum creatinine con-
centrations > 0.15 mmoles/liter were excluded, lin-
ear conversion for the remaining 12 recipients be-
came acceptable (r = 0.68), yielding Km (750
ji,moles/liter) and Vmax (19.5 j.tmol/hr/kg) values in-
termediate between control and CRF values.
Plasma lipases determined for the CRF and trans-
plant groups are compared with previously docu-
mented control values [4] in Table 4. In CRF, lipo-
protein lipase activity was reduced in both sexes,
and hepatic lipase activity in males. In transplant
recipients, lipase activities were similar to normals
with the exception of significantly increased hepatic
lipase activity in females. In no group, however,
could the activity of either lipase be correlated sig-
nificantly with the parameters of triglyceride turn-
over (V or K).
Discussion
Interpretation of the results of endogenous tri-
glyceride turnover studies is based on the hyper-
bolic relationship that exists between turnover and
substrate concentration in metabolic reactions ex-
hibiting first order kinetics. That the utilization of
VLDL-TG is governed by this hyperbolic relation-
ship has been shown both for nonuremic subjects
[6] and patients with CRF [7, 9, 10]. In the present
study, we derived our normal curve from 10 healthy
subjects, only one of whom was hyperlipidemic.
Despite the narrow range of VLDL-TG concentra-
tions, good linear conversion (r = 0.81) of the con-
trol turnover data was obtained. Furthermore, the
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Fig. 2. Relationship between VLDL-TG turnover rates and plasma VLDL-TG concentration in a 20 patients with undialyzed CRF (0),
and b /6 patients with kidney allografts, 12 with normal renal function (A), and 4 with serum creatinine >0.15 mmolesiiter (A),
compared with that in ten healthy control subjects (S). The rectangular hyperbola is derived from the control data (Table 3).
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Table 4. Postheparin lipolytic enzyme activities a
N
Hepatic lipase Lipoprotein lipase
j.unoles of NEFA hr1m/'
Males
Controls
CRF
Transplant
Females
Controls
CRF
Transplant
17b
9
10
15b
10
6
9.6 3.35•7 3d
9.4 4.1
5.3 1.5
3.9 2.1
9.4 3.6c
6.2 3.337 l.8
5.9 2.8
9.0 3.5
2.9 1.6'
10.1 5.1
a Results are the means so.
"Previously published control data [4]
P <0.05, significantly different from control group.
dP <0.01, significantly different from control group.
calculated Vmax (36.7 tmo1es/hr/kg) and Km (1375
moles/1iter) values for our normal subjects were
similar to those derived with the same method by
Reaven et al [6] from subjects with a broad range of
serum triglyceride levels.
The present study indicates that defective
VLDL-TG removal is the principal cause of hyper-
triglyceridemia in CRF, and to a lesser degree, after
renal transplantation. In 16 out of 20 patients with
undialyzed chronic renal failure, rates of VLDL-TG
production were clearly less than expected for a
given VLDL-TG concentration, that is, the coordi-
nates lay below and to the right of the normal curve.
Furthermore, the calculated group maximum turn-
over rate (Vmax) was far less in CRF (14.0 j.tmoles/
hr/kg) than in the normal subjects.
Four of the CRF group, however, had coordi-
nates that lay either on or above the normal turn-
over-concentration curve, and two of these had ele-
vated VLDL-TG concentrations. It follows that in
these two, hypertriglyceridemia was the result of in-
creased production rather than under-removal. But,
unlike Verschoor, Lammers, and Birkenhager [8]
who reported that the two patients who did not have
reduced VLDL-TG turnover in their series of 12
uremic patients, had relatively high creatinine clear-
ances, we were unable to show any difference be-
tween our two "overproducers" and the "under-
utilizers," either in respect of renal function or any
of the other variables examined, namely lipase ac-
tivities, insulin levels, drug therapy, or degree of
obesity. Moreover, triglyceride turnover did not
correlate significantly with creatinine clearance in
their entire series, or with serum creatinine in ours.
Other investigations have also shown that tri-
glyceride removal is impaired in both undialyzed
and dialysis-treated CRF [7—10]. Triglyceride turn-
over may not have been quite as low, however, as
estimated in these studies, for it appears that the
authors failed to take into account that plasma vol-
ume is commonly expanded in CRF. Animal data
also support the concept of defective VLDL clear-
ance as a mechanism for uremic hypertriglyceridemia.
In rats undergoing 5/6 nephrectomy,hypertriglycerid-
emia is evident after 3 weeks and associated with
a significant reduction in the fractional turnover rate
of VLDL-TG [22].
Postheparin lipolytic activity was reduced in
CRF. Of the two enzymes measured, lipoprotein
lipase (believed to be the more important in periph-
eral utilization of VLDL [23]) was depressed by
renal failure in both sexes, and hepatic lipase only
in males, conforming to the pattern noted in an ear-
lier study [4]. Although there has been no correla-
tion shown between enzyme activity and either frac-
tional or absolute or turnover rate of triglyceride,
this does not rule out a cause-effect relationship,
for neither the method of releasing the enzymes by
i.v. administration of a large dose of heparin nor the
conditions of in vitro assay (pH, temperature, syn-
thetic substrate) resembles the situation that per-
tains at the blood-tissue interface where peripheral
triglyceride utilization occurs. Uremic serum does in-
deed appear to contain a macromolecular inhibitor
of tissue [24] and circulating [25] lipases. Thus, it
seems possible that impaired enzyme activity might
be responsible for triglyceride under-utilization in
uremia.
After renal transplantation, hypertriglyceridemia
persisted but was less severe. Total triglycerides
and VLDL-TG were significantly related to serum
creatinine concentrations, an observation that im-
plies that transplant hypertriglyceridemia is due in
part to the fact that many transplants have impaired
function resulting in mild uremia.
With respect to VLDL-TG removal kinetics,
most transplant patients' coordinates also are below
and to the right of the normal hyperbola, again de-
noting an impaired capacity for VLDL-TG removal
as the cause of hypertriglyceridemia. In general, the
points are closer to the hyperbola, indicating a less
severe defect than that in CRF. There were two ex-
ceptions who were overproducers, and the ex-
tremes of overproduction and underremoval were
observed in patients with impairment of graft func-
tion. This finding is interesting in the light of the
observation in the above-mentioned animal model
that dexamethasone administration to the uremic
rats may cause both overproduction and decreased
fractional removal of VLDL-TG [22].
It was clear from the poor linear transformation
that transplant recipients as a whole did not con-
form to a single set of kinetic data. This did not
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seem surprising in view of the marked hetero-
geneity of the group in respect of time elapsed since
grafting, daily dose of prednisolone, and steady-
state renal function. Simple deletion of those recipi-
ents with impaired graft function resulted, however,
in satisfactory kinetic analysis in the remaining pa-
tients, and the derived Vmax, 19.5 fLmoles/hr/kg, a
result intermediate between the normals and the
CRF, confirmed a removal defect as the pre-
dominant mechanism in transplant triglyceridemia.
We could not identify, on a statistical basis, those
factors responsible for the disordered VLDL-kinet-
ics in the transplant recipients. Again, the hetero-
geneity of the group may have been responsible for
the failure of statistical trends to emerge. Certainly,
measured lipase activities were not reduced, in
keeping with the findings of others [2, 4]. Mild ure-
mia may be a factor leading to defective removal in
some recipients, and the additive effects of steroids
in these might cause extremes of overproduction
and under-removal. Nevertheless, impaired clear-
ance was observed even when graft function was
normal.
Ibels, Aifrey, and Weil [26] have found that pred-
nisone dosage is in part responsible for transplant
hypertriglyceridemia. Others have proposed that
prednisone causes over-production of triglycerides
in such patients [12]. Massive doses of methyl-
prednisolone certainly appear to do so, but do not
often result in hypertriglyceridemia [12]. Moreover,
when corticosteroids are administered to patients
without renal disease, there is a proportionately
greater rise in plasma cholesterol than there is in
triglyceride concentrations [27], yet mean choles-
terol levels in our graft recipients and in another
posttransplant group [12] were not increased. It is
possible that steroids may modulate triglyceride
turnover by other routes; for instance by causing
tissue resistance to insulin, which is believed to be
necessary for the induction of adipose tissue lipase
in vivo [28]. Such a mechanism would be consistent
with the kinetic observations in this study.
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